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1  BIOLOGICAL BACKGROUND 
1.1 ABC-Transporters 
1.1.1 Introduction 
 
The ATP-binding cassette (ABC) transporter superfamily is one of the largest classes of trans-
porters. By binding and hydrolyzing ATP, ABC-Transporters actively translocate substrates across 
membranes. They can function both, as importers, which carry nutrients and other molecules 
into cells, or as exporters, which are responsible for the active efflux of toxins, drugs and lipids 
out of the cell. Members of the ABC transporter family exist across all domains of life, which is 
an indication of their wide physiological roles. While importers appear to be present exclusively 
in prokaryotes, exporters are found in both eukaryotes and prokaryotes.1  
In this thesis I will focus on efflux systems, especially the human type of ABC transporters. There 
are 48 known human ABC transporters, which are divided into seven distinct subfamilies of pro-
teins (ABCA to ABCG).2 These transporters are for instance involved in cholesterol and lipid 
transport, antigen presentation, mitochondrial Fe homeostasis, the regulation of ion channels 
and multidrug resistance. Mutations in ABC genes have been related with a range of disorders 
such as cystic fibrosis, hypercholesterolemia and diabetes.1  
 
1.1.2 Structural Organization 
 
ABC-Transporters in general consist of two transmembrane (TM) domains, forming the trans-
membrane channel, and two nucleotide-binding (NB) domains, which are responsible for ATP 
binding and hydrolysis (Figure 1).  
 
 
Figure 1:   Schematic depiction of the structure 
of ABC transporters. The TM domains harbor the sub-
strate binding sites and thus are responsible for the 
translocation of the ligand. The NB domains bind and 
hydrolyze ATP, which provides the energy for drug 
transport. 
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ABC uptake systems, in contrast to export systems, include additional water-soluble substrate-
binding proteins capable of binding substrates, thus facilitating their respective delivery to the 
TM domains (Figure 2).1 
 
 
 
Figure 2:   Schematic depiction of the modular 
organization of ABC transporters with the binding 
protein component that is required by importers. 
Picture taken and modified from Rees et al.1  
 
 
 
 
Whereas the water-soluble NB domains are highly conserved throughout the ABC superfamily, 
the hydrophobic TM domains are rather diverse which leads to distinct substrate profiles of 
transporter subtypes. Each TM domain consists of several TM helices (most transporters have 6 
helices per monomer) that are connected via extra- and intracellular loops, also called cou-
pling helices. These loops are inter alia responsible for TM-NB domain communication.3 NB do-
mains include the Walker A and Walker B consensus sequence for nucleotide binding linked by 
the signature motif (linker dodecapeptide). The bound ATP molecule is sandwiched between 
the Walker A and B sequence of one monomer and the signature motif of the opposite mon-
omer. Thereby, the Walker A motif, also known as the phosphate-binding loop or P-loop, binds 
the nucleotide through electrostatic interactions with the triphosphate moiety.4 
 
1.1.3 Mechanisms of Transport 
 
Although there are a great variety of transported substrates, the mechanism of the catalytic 
cycle of ABC exporters appears to be universally valid.5 However, due to the small number 
and the low resolution of crystal structures of ABC-transporters, the concrete mechanism is still 
unclear.6 In the first step of the transport cycle the substrate binds to its high-affinity site at the 
TM domains. At that moment the protein is still in its basal state, an inward-facing conformation 
with the NB domains represented as ‘open dimer’. Ligand binding causes a conformational 
change that facilitates the binding of ATP resulting in a ‘closed dimer’ formation. Consequent-
ly a major conformational change in the TM domains is induced, leading to an outward-facing 
conformation of the transporter. Due to this structural rearrangement of the TM domain, the 
ligand binding site orients towards the extracellular space, which results in an affinity decrease 
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and the ligand is released to the external medium. Subsequent hydrolysis of ATP is necessary to 
return the transporter to its ‘open’ basal state.3,7,8 
 
1.1.4 Overview of Human ABC Gene Superfamilies 
 
The 48 known human ABC transporters are divided into seven distinct subfamilies of proteins, 
playing a vital role in many cellular processes like peptide transport, cholesterol and sterol 
transport, bile acid, retinoid and iron transport. Additionally, some ABC genes are important as 
regulatory elements. Furthermore, many of these genes are involved in human genetic diseas-
es or drug resistance. 2,9 A brief summary of each subfamily is shown below. 
 
ABCA (ABC1) 
 
The ABCA or ABC1 subfamily includes 12 full transporters, containing some of the largest ABC 
genes. ABCA1, one of the two extensively studied members of this subfamily, is involved in dis-
orders of cholesterol transport and high-density lipoproteins (HDL) biosynthesis. ABCA4, a retina 
specific ABC-transporter, is responsible for the transport of vitamin A derivatives in the outer 
segments of photoreceptor cells, which is an essential step in the visual cycle.2,10 
 
ABCB (MDR/TAP) 
 
This subfamily comprises four full and seven half transporters. The most intensively studied 
member of this group is the full transporter ABCB1, also known as P-glycoprotein. ABCB1, lo-
cated in epithelial cells of the blood brain barrier, kidney and liver for example, is known for its 
broad substrate specificity, thus playing an important role in removing toxic metabolites from 
cells. Furthermore, it also exports a high number of therapeutics, wherefore ABCB1 is strongly 
involved in the occurrence of multidrug resistance.2,10 
 
ABCC (CFTR/MRP) 
 
The 12 full transporters of this subfamily have a fundamentally diverse functional spectrum that 
involves iron transport, cell surface receptor, and toxin secretion activities. The chloride ion 
channel CFTR (cystic fibrosis transmembrane conductance regulator) has a role in all exocrine 
secretions, in which mutations in CFTR cause cystic fibrosis. Other mentionable transporters are 
ABCC8 and ABCC9, which bind sulfonylurea and regulate potassium channels participating in 
modulation of insulin secretion.2,10 
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ABCD (ALD) 
 
All of the four half transporters of this subfamily are necessary for the regulation of very long 
chain fatty acid transport.2,10 
 
ABCE (OABP) and ABCF (GCN20) 
 
Although the proteins of the ABCE and ABCF subfamilies have ATP-binding domains that are 
clearly derived from ABC transporters, they have no TM domain, thus no transport can be ob-
served.2,10 
 
ABCG (White) 
 
This subfamily includes five half-transporters, from which ABCG1 was described first as being 
involved in lipid metabolism. Later on, it was shown that also the members ABCG5 and ABCG8 
are playing a role in the lipid metabolism. Furthermore, mutations of these genes cause sitos-
terolemia, a rare heritable disorder.  
ABCG2 is also known as BCRP1 (breast cancer resistance protein) and belongs, like ABCB1, to 
the group of multidrug transporters. Similar to ABCB1 it shows a broad substrate profile and 
could be related to multidrug resistance.2,10 
 
1.1.5 ABC Genes and Human Disorders 
 
As shown in the preceding chapter, a wide variety of human disorders are associated to dys-
function of ABC transporters, including multidrug resistance and inherited diseases caused by 
mutations in human ABC proteins.2 
 
In humans, multidrug transporters, as ABCB1 (P-glycoprotein), ABCC1 (MRP1) and ABCG2 
(BCRP), have been identified as proteins associated with acquired multidrug resistance (MDR) 
in cancer cells. Primarily intended to protect cells that are exposed to xenobiotics, these multi-
drug transporters also extrude several classes of anticancer drugs, thus decreasing the drug 
concentration inside the target cells. Especially when the transporters are overexpressed, this 
can lead to MDR, in which the cell is resistant to several drugs in addition to the initial com-
pound.11,12  
 
Genetic variation in ABC genes is the reason of a wide variety of human inborn or acquired 
diseases. At the moment 17 different transporters are associated with a defined human dis-
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ease, including cystic fibrosis, neurological disease, retinal degeneration and cholesterol and 
bile transport defects. A summary of these disorders, which are due to reduction or absence of 
function of the transporter, and the corresponding genes is shown in Table 1.2,11,12 All of these 
disorders displaying Mendelian inherence are recessive due to the fact that ABC genes mostly 
encode structural proteins. A new promising class of therapeutic agents for correcting misfold-
ing and preventing assembly caused as a result of this gene defects are pharmacological 
chaperones,13 which are described in the next chapter. 
 
 
 
Table 1. Human Inherited Diseases Associated With ABC Transporter 
Disease ABC transporters 
Tangier disease and familial HDL deficiency ABCA1 (ABC1) 
Surfactant deficiency ABCA3 (ABC3, ABCC) 
Stargardt disease and age related macular degeneration ABCA4 (ABCR) 
Lamellar ichtyosis ABCA12  
Immune deficiency ABCB2 (Tap1), ABCB3 (Tap2) 
Progressive familial intrahepatic cholestasis 3 (PFIC 3) ABCB4 (PGY3) 
Sideroblastic anemia and ataxia ABCB7 (ABC7) 
Progressive familial intrahepatic cholestasis 2 (PFIC 2) ABCB11 (MRP8) 
Dubin-Johnsin syndrome ABCC2 (MRP2) 
Pseudoxanthoma elasticum ABCC6 (MRP6) 
Cystic fibrosis ABCC7 (CFTR) 
Familial persistent hypoglycemia of infancy ABCC8 (SUR1) 
Dilated cardiomyopathy with ventricular tachycardia ABCC9 (SUR2) 
Adrenoleukodystophy ABCD1 (ALD) 
Sitosterolemia ABCG5, ABCG8 
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1.2 Pharmacological Chaperones 
1.2.1 Introduction 
 
Proteins that are targeted to the cell surface or other organelles, or are exported from the cell, 
are synthesized and folded in the endoplasmic reticulum (ER) before they are delivered to 
their final destinations. Over 1600 human diseases are discovered as a result from missense mu-
tations that lead to misfolded proteins. A missense mutation is a heritable change of a single 
base in a coding region of a gene, evoking an amino acid change in the corresponding pro-
tein. These point mutations can inhibit folding and cause assembly of the protein in the ER. 
Consequently, the underlying defects in diseases can be divided into two broad categories, 
either the accumulation of toxic aggregated forms of the protein or the premature clearance 
of functional proteins that are wrongly recognized as incorrectly folded by the quality control 
systems. Using chemical or pharmacological chaperones could be a potential therapy to cor-
rect defective protein folding and trafficking.13–15 
 
The term pharmacological chaperones or pharmacochaperones, as well as chemical chap-
erones, is derived from molecular chaperones, which describes a class of proteins that func-
tion in living cells. These molecular chaperones are huge proteins, which have important pur-
poses during the folding process of cell proteins by protecting the nascent polypeptide chain 
from unfavorable associations in the usually crowded environment of the cell until it can fold 
properly. A relatively high percentage of protein molecules are often unfolded or misfolded, as 
they are only slightly stable under physiological conditions. Molecular chaperones also prevent 
unwanted associations of unfolded or misfolded proteins, insulating them and providing an 
environment in which they have the opportunity to refold correctly. Contrary to these protein 
chaperones, chemical and pharmacological chaperones are small molecules. Instead of as-
sisting in folding, they typically stabilize an already folded protein by binding to it.16 
 
1.2.2 Chemical Chaperones 
 
Chemical chaperones are a group of low-molecular-weight compounds including polyols, 
such as glycerol, trimethylamines, such as trimethylamin N-oxide, and amino acid derivatives. 
These compounds promote folding by stabilizing proteins without covalently binding to them, 
therefore they are able to reverse the mislocalization or aggregation of proteins associated 
with human disease. Although the mechanism by which chemical chaperones work is not fully 
understood, it is generally assumed that they stabilize a conformation capable of escaping 
the quality control system. Other possible mechanisms include reduction of aggregation, pre-
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vention of nonproductive interactions with other proteins and alteration of the endogenous 
chaperones, so the affected proteins are more efficiently transported to their correct destina-
tion. Unfortunately, chemical chaperones have general effects on multiple proteins making it 
impossible to use them in vivo. Contrary to this, pharmacological chaperones are thought to 
affect only the specific protein with which they interact.14,17 
 
Figure 3:  Schematic depiction 
of a G-protein-coupled receptor 
retained in the endoplasmic reticu-
lum rescued with a chemical chap-
erone, such as Trimethylamine N-
oxide. As an osmolyte it is able to 
diffuse into the cell where it assists 
the folding of many different pro-
teins in various cellular compart-
ments without specificity for the 
disease related protein. Picture tak-
en and modified from Bernier et al.14 
 
 
 
 
1.2.3 Pharmacological Chaperones 
 
Pharmacological chaperones or pharmacochaperones are specific hydrophobic active-side 
ligands that can diffuse into the cell, in which they could overcome folding defects in pro-
cessing mutants by stabilizing folding intermediates in the endoplasmic reticulum. Loo & Clarke 
first demonstrated the rescue of processing mutants of P-glycoprotein with pharmacological 
chaperones.18 They observed mature and active P-glycoprotein at the cell surface after ex-
pressing a processing mutant in the presence of different drug substrates like capsaicin, cyclo-
sporine A, verapamil or vinblastine. This effect could be explained by the occupation of the 
drug-binding site in an early state during biosynthesis, which results in stabilization of a folding 
intermediate in a near native conformation that can escape the quality control system. The 
advantage of pharmacological chaperones is that only the folding of the protein that is selec-
tively targeted by the ligand will be influenced. Besides P-glycoprotein and other ABC trans-
porters, many outer proteins can be rescued with pharmacological chaperones from pro-
teasomal degradation, including G-protein coupled receptors (GPCRs) and lysosomal storage 
disease related proteins. Defects in GPCRs lead to Parkinson disease, hypogonadotropic hy-
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pogonadism or nephrogenic diabetes insipidus, respectively. Lysosomal storage diseases, 
caused by deficient activity of a lysosomal hydrolase, include Fabry disease, Gaucher disease 
and Tay-Sachs disease.13,14 As this study is based on the ABC-Transporter P-glycoprotein, a se-
lection of defect ABC-transporters rescued by pharmacological chaperones is given below. 
 
Figure 4:  Schematic depiction 
of a G-protein-coupled receptor re-
tained in the endoplasmic reticulum 
rescued with a non-peptidic antago-
nist as a pharmacochaperone. The 
antagonist specifically binds to the 
protein and stabilizes it in a confor-
mation that is released by the endo-
plasmic reticulum quality control sys-
tem, allowing the receptor to reach 
the cell surface. Picture taken and 
modified from Bernier et al.14 
 
 
 
 
1.2.4 ABC-Transporters Rescued with Pharmacological Chaperones 
 
As mentioned before, 48 different ABC-Transporters are expressed in human, out of which 14 
have been linked to human diseases. Many of these problems are due to the presence of 
processing mutations in an ABC transporter. Two of these proteins are discussed below. 
 
ABCB7 – CFTR  
 
Mutations in the gene coding for the cystic fibrosis transmembrane conductance regulator 
(CFTR) cause cystic fibrosis, an autosomal recessive disorder. CFTR, which is a cAMP-activated 
chloride channel, is responsible for regulation of salt and fluid transport at the apical surface of 
epithelial cells. Thus, in cystic fibrosis the lack of chloride channel activity is characterized by 
abnormal transport of chloride and sodium across the epithelium, leading to mucosal obstruc-
tion of ducts within a variety of organs such as liver, pancreas or lungs. The main causes of 
morbidity are chronic lung infections, resulting in a decline in respiratory function and subse-
quent lung failure. In the Caucasian population one in 25 persons is a carrier of the defective 
CFTR gene. Furthermore cystic fibrosis affects 1 in 2500 live births. Over one thousand disease-
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associated mutations have been identified in the CFTR gene whereas the most common cystic 
fibrosis associated mutation is the deletion of phenylalanine 508 in the first NB domain. Nearly 
all of the F580 CFTR accumulates in the ER and is rapidly degraded due to a temperature-
sensitive defect in folding, resulting in an almost complete loss of cellular CFTR function, 
whereas it appears that the mutation does not cause misfolding but incomplete folding result-
ing in accumulation of the protein. In the last few years several classes of correctors were iden-
tified acting as pharmacochaperones for CFTR.13 
 
ABCC8 – SUR1 
 
The sulfonylurea receptor-1 (SUR1) forms together with Kir6.2 the ATP-sensitive potassium chan-
nel of the pancreatic β cell, which regulates insulin secretion in response to blood glucose lev-
els. High glucose levels increase the ATP/ADP ratio in the β cell of the pancreas. The resulting 
binding of ATP to KATP inhibits potassium channel activity, which induces the opening of volt-
age-dependent calcium channels. The resulting calcium influx acts as a signal for insulin re-
lease. Consequently, the glucose level descends and the ATP/ADP ratio falls, which leads to 
an increased binding of ADP to KATP, and thus an opening of the KATP channel and closing of 
the voltage-dependent calcium channels occurs. Mutations in SUR1 that interfere with folding 
lead to the loss of functional KATP channels, as delivery of both SUR1 and Kir6.2 to the cell sur-
face is inhibited. The absence of the KATP channels at the cell surface results in the calcium 
channels remaining open and causing the β cells to release insulin even when glucose levels 
fall, which leads to persistent hyperinsulinemic hypoglycemia of infancy. Sulfonylureas and 
glinides, oral hypoglycemic drugs that inhibit the KATP channels by binding to SUR1, act as 
pharmacological chaperones by promoting maturation of SUR1 mutants, which leads to a 
functional KATP complex at the cell surface.19 
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1.3 P-glycoprotein 
1.3.1 Introduction 
 
The best characterized ABC drug pump is ATP-binding cassette sub-family B member 1 
(ABCB1), also known as multidrug resistance protein 1 (MDR1) or P-glycoprotein (P-gp), which is 
expressed by the mdr1 gene. P-glycoprotein is an ATP-dependent drug efflux pump that de-
toxifies cells by exporting hundreds of chemically diverse xenobiotic compounds ranging from 
330 daltons up to 4.000 daltons.20 As one major physiological role of P-glycoprotein is the pro-
tection of the organism against potentially toxic compounds it is extensively expressed in the 
apical membrane of epithelial cells in the body. P-glycoprotein can also be found in the 
blood-brain barrier, the blood-testis barrier, the blood-nerve barrier, and in the placenta.21 
However, the membrane-associated protein is also expressed in cancer cells, thus, among 
others responsible for multi drug resistance, as disease related overexpression results in the ex-
trusion of therapeutic drugs.20 
 
1.3.2 Structural Organization and Mechanism of Transport 
 
P-glycoprotein is a 170 kDa glycosylated plasma membrane protein that is composed of 1.280 
amino acids.22 In 2009 Aller et al. published the crystal structure of mouse P-glycoprotein, 
which shares 87 % of its sequence with the human homolog.20 As an ABC full transporter, P-
glycoprotein is a heterodimer consisting of two transmembrane (TM) and two nucleotide bind-
ing (NB) domains. The two homologous halves are joined by a linker region, consisting of about 
60 amino acid residues. Each half contains six amino-terminal hydrophobic TM helices followed 
by a large hydrophilic cytoplasmic NB domain. The nucleotide free inward facing confor-
mation, which is capable to bind drugs, results in a large internal cavity open to the cytoplasm 
as well as the inner leaflet. Two portals, formed by TMs 4 and 6 and TMs 10 and 12, allow en-
trance of hydrophobic molecules directly from the membrane. The large drug-binding pocket 
is made of mostly hydrophobic and aromatic residues. Substrate stimulated ATP binding caus-
es a dimerization in the NB Domains, which evokes large structural changes, resulting in an 
outward-facing conformation. Thus, as a consequence of decreased binding affinity, the sub-
strates are released to the external medium (Figure 5). However, ATP hydrolysis disrupts NBD 
dimerization and sets the system back to its initial inward facing conformation.20  
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Figure 5: Depiction of the proposed mechanism of substance transport across cell membranes. 
(a) The ligand enters the binding site from the inner leaflet of the membrane in the high affinity state of 
the protein. (b) ATP (yellow stars) binds to the NBD followed by a large conformational change and re-
lease of the ligand into the extracellular space. Picture taken and modified from Ishrat Jabeen23 
 
1.3.3 Model System for Pharmacochaperone Activity 
 
Human P-glycoprotein, known for its ability to induce multidrug resistance, has been a useful 
model system for studying the mechanism of rescue with pharmacological chaperones due to 
the fact that truncation mutants as well as processing mutants (mutations scattered through-
out the molecule) can be corrected.13 
 
During its synthesis P-glycoprotein undergoes some co-translational folding to yield a biosyn-
thetic intermediate, where the four domains of the protein are arranged in a loosely associat-
ed conformation and packing of the TM segment is incomplete. The protein then matures as 
contacts form tight interactions between the four domains. The arisen compact structure al-
lows the protein to leave the endoplasmic reticulum and enter the Golgi complex where the 
high-mannose carbohydrate groups are modified, becoming complex carbohydrates. Finally 
the mature protein is delivered to the cell surface in a functional form. To be retrieved from the 
plasma membrane proteins at the cell surface can undergo endocytosis, in which the protein 
can be recycled to the plasma membrane or targeted for degradation in the lysosome (Fig-
ure 4a).13 
 
In P-glycoprotein deletion of tyrosine 490 (Y490), which is equivalent to the phenylalanine 508 
(F508) mutation of the cystic fibrosis transmembrane conductance regulator (CFTR)24, hinders 
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maturation and delivery of the transporter to the cell surface due to the fact that the molecule 
does not complete the folding process. However, these folding intermediates are retained in 
the endoplasmic reticulum and targeted for degradation by cytosolic proteasomes (Fig-
ure 4a).13  
 
Expression of an Y490 mutant of P-glycoprotein in the presence of a pharmacological chaper-
one, such as drug substrates or inhibitors, promotes compact folding of the molecule by bind-
ing at the interface between the two TM domains to yield a protein that can be delivered to 
the cell surface in a functional form18 (Figure 4b). Consequently both TM domains are required 
for drug rescue whereas truncation mutants lacking both NB domains can still be rescued.25  
  
 
 
 
Figure 4: Depiction of a P-glycoprotein processing mutant corrected with a pharmacochaperone.  
(a) Synthesis of wild-type (green model) and mutant P-glycoprotein (red and green model) is shown.  
(b) Expression of mutant P-glycoprotein in the presence of a pharmacological chaperone (purple ovals). 
Picture taken and modified from Loo & Clarke.13 
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2  AIM OF THE STUDY 
 
Overexpression of P-glycoprotein is a major reason for multidrug resistance (MDR) and thus 
responsible for the failure of antibiotic and cancer therapies. Therefore, inhibitors of  
P-glycoprotein are promising candidates for overcoming the problem of MDR. Inhibitors of  
P-glycoprotein appear also to be acting as powerful pharmacological “chaperones” for pro-
cessing misfolded P-glycoprotein. P-glycoprotein is a useful model system for studying the 
mechanism of rescue with pharmacological chaperones because truncation mutants as well 
as processing mutants (mutations scattered throughout the molecule) can be corrected.  
 
It has been shown that the inhibitor and pharmacological chaperone GPV062 may repair the 
folding defects either by promoting dimerization of the two nucleotide binding (NB) domains 
or by promoting correct folding of the transmembrane (TM) domains. 
 
The aim of this work was to develop in silico models based on a binding hypothesis for GPV062, 
which can be used to perform virtual screening for the identification of new inhibitors, as well 
as pharmacochaperones for P-glycoprotein. In that sense, a combined approach applying 
structure, as well as ligand based methods should be performed.  
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3  COMPUTATIONAL BACKGROUND 
3.1 Structure Based 
3.1.1 Introduction 
 
Today structure based drug design is an essential part of most industrial drug discovering pro-
grams and remains a major subject of research for many academic laboratories. Structure 
based drug design requires knowledge of the three dimensional structure of the biological 
target, which can be determined through methods such as X-ray crystallography or NMR 
spectroscopy. Unfortunately there is lack of success of these two methods regarding mem-
brane proteins. This is a serious problem because many important pharmacological targets are 
membrane receptors and transporters. Thus it is often necessary to create a homology model 
of the target based on the experimental structure of a related protein.  
The generated structure can be further used to analyze intermolecular drug-protein interac-
tions, to predict the affinity of new compounds or to virtually screen for new drug candidates.26  
 
3.1.2 Homology Modeling 
 
If no crystal structure of a protein is available, homology protein structure modeling is a good 
method to build a three-dimensional (3D) model. There are two different approaches in ho-
mology modeling: ab initio or de novo method and comparative modeling. Although the for-
mer is the more accurate method, it is computationally very expensive and can only be ap-
plied to small polypeptide chains. Because of that, comparative modeling is the method of 
choice for the generation of 3D protein models.  
With this method the tertiary (sometimes also quaternary) structure of a given protein se-
quence (target) is principally predicted on basis of its alignment to one or more proteins of 
known structure (templates). To build a useful model the similarity between the target and the 
template must be detectable, leading to a significantly correct alignment of the sequences. 
As 3D structures of proteins in a family are evolutionary more conserved than their sequences, 
structural similarity can normally be assumed if similarity between two proteins is detectable at 
the sequence level. As depicted in the workflow in Figure 6, the steps of the prediction process 
are fold assignment and template selection, target-template alignment, model building, and 
model evaluation. If the model is not satisfactory, these steps can be repeated until an ac-
ceptable model is received (Figure 6).27 The received model can be used to predict protein-
protein interactions as well as for protein-protein docking or molecular docking.  
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Figure 6: Steps of Homology Modeling, picture taken from Martí-Renom et al.27 
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3.1.3 Docking 
 
The docking process is a method that predicts the preferred conformation and orientation (or 
posing) of one molecule to a second (Figure 7). Depending on the molecule type, small-
molecule-protein docking methods and protein-protein docking methods can be distin-
guished. However, this thesis will focus on small-molecule-protein docking.  
Figure 7: Schematic depiction of the docking process,  
illustrating the binding of a ligand to a protein receptor to produce a complex. 
 
Generally there are three main purposes for docking studies:  
• The prediction of the binding mode of a known substrate/inhibitor in the protein’s ac-
tive site.  
• If only the protein structure is available, docking can be used as virtual screening 
method for identifying potentially active compounds. 
• Another purpose for docking is the prediction of binding affinities of (active) com-
pounds in the binding site.28  
 
Docking is commonly contrived as a multi step progress, which starts with the recognition, 
identification and characterization of the binding site. The second step would be the place-
ment of the ligand, during which possible orientations and interactions are found, leading to a 
number of generated docking poses. Scoring of the docking pose represents the third and last 
step of the docking experiment. It is intended to evaluate the interactions between ligand and 
receptor and rank the docking poses accordingly.29  
 
Binding Site Identification 
 
Molecular docking can be illustrated as a problem of “lock and key”, in which the “key” repre-
sents the ligand and the “lock” the binding site of the receptor. Thus accurate determination 
of the binding site is crucial for the docking process. Shape complementary, as described in 
the “lock and key” model is basis of most binding site identification methods. Additionally phys-
ico-chemical complementary like van-der-Waals interactions, electrostatic interactions, hy-
drogen bonds, pi-pi interactions and solvent interactions are criteria in binding site detection.29  
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To detect potential binding pockets there are several programs using different algorithms 
available. These programs scan the protein surface for cavities that match geometrical con-
straints, marking them as possible ligand binding sites. Furthermore, the protein can be 
scanned with fragments of ligands with subsequent calculation of their complementary in or-
der to consider physico-chemical complimentary.  
Another approach for binding site identification can be achieved by comparing the query 
protein with homologous proteins that share similar binding sites. Therefore the protein surface 
is compared with surfaces of a database.30 Once the binding site is identified, it has to be 
characterized to get information of specific binding possibilities through non-covalent interac-
tions, which is achieved for example through the program GRID.31 
 
Placement of the Ligand 
 
Next step in the docking process is the correct placement of the ligand in the binding pocket. 
Therefore several placement algorithms, also called search algorithms, are available. These 
algorithms should consider all degrees of freedom of the system, which leads to higher accu-
racy. Due to limitations regarding computer power, a balance must be found between speed 
and accuracy. Therefore approximations need to be done. There are mainly 3 rigid body ap-
proximations to be distinguished29 (Figure 8): 
 
 
Figure 8: Schematic depiction of the 3 rigid body approximations. 
 
Three different types of algorithms are devised to treat ligand flexibility: systematic methods, 
stochastic methods and simulation methods. 
 
The systematic search algorithms can be further divided in three main types: conformational 
search methods, fragmentation methods or database methods.  
Conformational search methods rotate every rotatable bond of the ligand in fixed increments. 
Although this method is able to scan the whole conformational space, it can only be applied 
for small or rigid ligands to avoid combinatorial explosion.  
In contrast to this, fragmentation methods place ligand fragments in the binding pocket, 
where they are finally fused.  
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Computationally very efficient is the database method, which represents another way to 
search for possible orientations. For this approach a conformational library of the ligand has to 
be prepared in advance. Every conformation of the ligand is then docked rigidly into the bind-
ing site.32 
 
Stochastic principles for binding mode prediction screen the conformational space by per-
forming random changes to the ligand. These changes are either kept or rejected based on a 
predefined probability function at each step. Among others genetic algorithms provide a use-
ful tool for this purpose. Therefore a random population of possible ligand poses is generated, 
in which each conformation is defined by a set of state variables and stored in its genetic 
code (chromosome). By applying genetic operators like mutations or crossovers to the popula-
tion new poses are generated, until an optimized final population is reached.32 This protocol is 
included in the docking program GOLD33,34, which is used for the docking studies in this theses. 
 
Simulation methods employ a rather different possibility to consider ligand flexibility. There are 
two major types: molecular dynamics (MD) and pure energy minimization methods, although 
MD is currently the most popular simulation approach. The MD simulation of the ligand in the 
binding pocket could be a versatile and powerful tool in the study of a wide range of applica-
tions. In contrary to these MD methods energy minimization methods are mainly used in com-
bination with other search algorithms.35  
 
However, the more flexibility is given to the system, the more accurate results can be 
achieved. Thus flexible protein docking methods gained more and more importance. Due to 
computational limitations it is not possible to cover the large structural changes that some pro-
teins undergo in reasonable time and effort. Therefore efficient workarounds have been de-
veloped. One possibility to account small movements of the protein side chains is soft docking, 
in which certain side chains in the binding pocket tolerate overlap with ligand atoms.36 Anoth-
er opportunity to get the receptor flexible is the use of rotamer libraries, which include the 
movements of side chains in the search algorithm.37 Unfortunately large structural movements 
cannot be covered with this approach, as the backbone is kept rigid. Thus, the induced fit 
docking protocol of the Schrödinger Suite38 is a hybrid technique that is commonly used to 
encounter protein flexibility. Therefore the ligand is docked into the rigid binding pocket. Sub-
sequently amino acid residues around the ligand are removed and rebuilt. 
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Scoring the Docking Pose 
 
To evaluate the quality of a docking run the application of a scoring function is necessary. 
Therefore several scoring functions are available which can be divided into three major clas-
ses: force field-based, empirical and knowledge-based scoring functions.32 
 
Force-field based scoring functions describe the energy by adding the internal energy of the 
ligand and the interaction energy between the ligand and the protein. Hence a combination 
of van der Waals interaction and electrostatic interaction is taken into account. Also the 
desolvation energies of the ligand and of the protein are considered using implicit solvation 
methods.32 There are several force field scoring functions available, including GoldScore34, 
which is used among others for the docking experiment in this theses.  
 
Empirical scoring functions estimate binding free energy on the basis of a set of weighted 
terms. Therefore the number of various types of interactions between the two binding partners 
is counted, based on different terms, including the number of hydrogen bonds or hydrophobic 
– hydrophobic contacts.32 Numerous scoring functions belong to this group, including Chem-
Score34, and X-SCORE 39 which are also used for the docking experiment. 
 
Knowledge-based scoring functions use very simple atomic interactions-pair potentials, based 
on the frequency of occurrence of different typical interactions in large datasets of protein-
ligand complexes of known structure.32  
 
Finally consensus scoring functions have also been developed in which the information ob-
tained from different scores is combined into one function.  
The choice of the scoring function strongly depends on the research query. Whatever scoring 
function is the most suitable for the request, limitations in the scoring function should be kept in 
mind when looking at the results. In order to allow a more computationally efficient evaluation 
of ligand affinity, scoring functions make a number of simplifications and assumptions at the 
cost of accuracy. Thus, a number of determinant physical phenomena are not fully account-
ed or even completely ignored. For example entropy contributions are often not considered 
and as a consequence large and polar molecules tend to be scored best.32  
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3.2 Ligand Based 
3.2.1 Introduction 
 
In contrast to structure based drug design, ligand based methods gain their information only 
from known ligands of the target in question. The main applications of ligand-based studies 
are similarity analysis (selection of compounds with similar activity to the known active com-
pound) and derivation of Quantitative Structure-Activity Relationship (QSAR), which describes 
connections between the structure and the activity of molecules in a quantitative way. Ligand 
similarity is also used for ligand based virtual screening (LBVS). Although structure based virtual 
screening (SBVS) applications were more frequent then LBVS applications with a 3:1 ratio40 
(Figure 9), LBVS plays an important role in virtual screening, especially when the structure of the 
receptor is missing. In this thesis LBVS is used as a second approach to find new pharmaco-
chaperones for P-gp. 
 
 
Figure 9: Ripphausen et al.40 surveyed 12 journals for prospective VS publications that have appeared 
between 1997 and 2010 (including July 15th). The illustration shows a classification of virtual screening 
applications, which were classified according to the computational methods that were used. Picture 
taken from Ripphausen et al.40 
 
However, the identification of the most informative representation of molecular structures plays 
an important role in ligand-based studies. Therefore a variety of descriptors, translating a 
chemical structure into a number, which preferentially describes a distinct physicochemical 
property of the compound, have been developed. Up to now, more than 4.880 different de-
scriptors are available41, ranging from simple descriptors that are often only based on the mo-
lecular formula (e.g. molecular weight or atom counts) to complex descriptors based on 
shape or distribution of features on the molecule.42 
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3.2.2 SHED-Similarity 
 
In 2006 Gregori-Puigjané and Mestres43 presented a novel set of molecular descriptors called 
SHED (Shannon Entropy Descriptors). This set processes chemical information of the molecule 
from the information-theoretical concept of Shannon entropy, representing a way to quantify 
the variability displayed by topological distributions of atom-centered feature pairs in mole-
cules.  
 
Process of Obtaining SHED (Figure 10) 
 
As a first step each atom in a molecule is mapped to a Sybyl atom type44, which is in the next 
step assigned to one or more of four atom-centered features:43 
 
• Hydrophobic (H) 
• Aromatic (R) 
• Acceptor (A) 
• Donor (D) 
 
Subsequently, the shortest path length between atom-centered feature pairs is derived and 
stored to generate a feature-pair distribution. To define the variability of feature-pair distribu-
tions, the concept of Shannon entropy45 is applied, in which the entropy, S, of a population, P, 
is distributed in a certain number of bins N (representing path lengths). ρi describes the proba-
bility and pi the population at each bin i of the distribution.43 
 ! =   −      !!!!!! ln!!                                 !! = !!/! 
 
Entropy values are then transformed into projected entropy values E in respect to have a more 
intuitive measure.43 
 ! =   !! 
 
These E values constitute the SHED profiles of a molecule, which are represented using a wheel 
chart (Figure 10).43 
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Figure 10: Depiction of the generation of a SHED profile.  
Picture taken from Gregori-Puigjané and Mestres43 
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3.3 Pharmacophore Modeling 
3.3.1 Introduction 
 
According to the definition by IUPAC46 “a pharmacophore is the ensemble of steric and elec-
tronic features that is necessary to ensure the optimal supramolecular interactions with a spe-
cific biological target structure and to trigger (or to block) its biological response.” A pharma-
cophore model can be conceived either from a set of active ligands (ligand-based) or from a 
receptor binding site by examining potential interactions points (structure-based). Basically, 
pharmacophore features include hydrogen bond acceptors or donors, hydrophobic spheres, 
aromatic rings and positive or negative ionizable features. Furthermore, these pharmacophor-
ic features can be combined with exclusion volumes constraints. Pharmacophore models are 
mainly used to identify novel ligands through virtual screening or de novo design (Figure 11).47–
49  
 
Figure 11: Depiction of the workflow of Pharmacophore modeling and applications. 
Picture taken from Yang S.48 
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3.3.2 Ligand-based Pharmacophore Modeling 
 
A ligand-based pharmacophore can be considered as the highest common denominator of 
a set of known active ligands. Therefore common chemical features from 3D structures of the 
training set are extracted and subsequently aligned. Creating the conformational space for 
each ligand and aligning the multiple ligands represent the key techniques as well as the main 
difficulties in ligand-based pharmacophore modeling. Two strategies are used for the model-
ing of ligand flexibility, the pre-enumerating method and the on-the-fly method. The pre-
enumerating method calculates multiple conformations for each molecule and saves them in 
a database. Conformation analysis in the on-the-fly method is directly involved in the pharma-
cophore modeling process.  
 
The second challenging issue in ligand-based pharmacophore modeling is molecular align-
ment. There are mainly two categories of molecular alignment methods, which can be distin-
guished according to their fundamental nature into point-based algorithms, in which pairs of 
atoms, fragments or chemical feature points are superimposed using a least-squares fitting, 
and property based algorithms, which make use of molecular field descriptors to generate 
alignments.48 However, ligand-based pharmacophore modeling is a key computational strat-
egy for drug discovery, although structure-based pharmacophore modeling suggests itself as 
an alternative, particularly if the 3D structure of the receptor is available. 
 
3.3.3 Structure-based Pharmacophore Modeling 
 
The best method of deriving a model for drug-receptor interaction is to examine a molecule’s 
complementarity with the target-binding site. Thus, the complementary chemical features of 
the active site and their spatial relationships based on a crystal structure or a homology model 
are analyzed to receive a pharmacophore model assembly with selected features. These 
models can be obtained either from a macromolecule-ligand-complex or from a macromole-
cule without ligand based on the set of pharmacophoric features mentioned before, including 
exclusion spheres. The obtained pharmacophore model can be used to identify the ligand 
binding mode and subsequently for virtual screening to identify new active compounds with 
the same binding mode but a different scaffold than the initial structure.48 
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3.3.4 Pharmacophore-based Virtual Screening 
 
The previously generated pharmacophore model can be used for querying a chemical data-
base to search for new potential ligands. The great advantage here is that, in contrast to 
docking based VS, the problems arising from inadequate consideration of protein flexibility or 
the use of insufficient scoring functions can be disregarded, as a tolerance radius for each 
pharmacophoric feature is introduced. The purpose of virtual screening is to discover new 
compounds that have chemical features comparable to those of the template, but different 
scaffolds. This kind of approach is also called scaffold hopping. There are two key techniques 
involved in the screening process, on the one hand the conformational flexibility of small mol-
ecules and on the other hand pharmacophore pattern identification. For the former either 
pre-enumerating multiple conformations for each molecule or conformational sampling at 
search time handles the flexibility of small molecules, which is very similar to those methods 
used in ligand based pharmacophore modeling. The second key technique, pharmacophore 
pattern identification, also called substructure searching, is determining if the pharmacophoric 
features are present in a given conformer of a molecule. The more features the molecule in 
question hits the higher is the so-called pharmacophore fit score. However, pharmacophore-
based virtual screening has become a well-accepted technique to identify new com-
pounds.48 There are various programs for pharmacophore modeling and subsequently VS 
available. In this thesis the program LigandScout50, which provides a tool for generating phar-
macophore models on basis of a drug-receptor complex, was used for the pharmacophore 
based virtual screening task. 
  
27 
4  MATERIALS AND METHODS 
4.1 Generation of the Pharmacophore Model 
 
Firstly, the aim of this study was the generation of a structure-based pharmacophore model, 
based on a validated docking pose published by Klepsch et al.51. Therefore, the docking pose 
of the propafenone derivate GPV062 in binding mode I was used as a starting geometry (Fig-
ure 12). 
 
 
Figure 12:  Depiction of the validated dock-
ing pose used for pharmacophore modeling (by 
Klepsch et al.51) 
(a) Final docking pose of GPV062 docked into a 
homology model of P-gp 
(b) Detailed side view of the docking pose, 
showing the hydrogen bond between Tyr310 
and the carbonyl group of the ligand 
(c) 2D ligand interaction plot of the validated 
docking pose of GPV062 docked into the P-gp 
homology model. 
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The LigandScout program package of Inte:Ligand GmbH50, providing a tool for generating 
pharmacophore models on basis of drug receptor complexes, was used for the construction 
of the structure-based pharmacophore model. Several models have been built, considering 
the three phenyl-rings, the nitrogen and the hydroxy group of the 4-hydroxy-4-piperidyl moiety 
from GPV062 as essential for activity. The phenyl-rings could be handled either as aromatic or 
as hydrophobic feature. Also the nitrogen atom could be treated in two different ways. On the 
one hand studies showed that the hydrogen bond acceptor strength of the nitrogen rather 
than its positive charge is important for higher activity52. On the other hand recent experiments 
suggested the tertiary nitrogen atom to be protonated53. Therefore, the nitrogen could either 
be considered as a hydrogen bond acceptor or as a positive ionizable group. The previous 
mentioned 4-hydroxy group is supposed to be the most essential feature of the pharmaco-
phore, due to the fact that propafenone derivatives with this group show a significantly higher 
activity/logP ratio. This indicates the presence of an H-bond between the 4-hydroxy group and 
the protein. Thus, H-bond acceptor, H-bond donor or both features have been considered for 
this atom. In addition to chemical features excluded volume coats were added in positions 
that are sterically claimed by the protein environment, which are likely to further increase the 
enrichment in virtual screening runs. 
 
 
Figure 13:  Pharmacophoric feature depiction in 
LigandScout50 used for generating the structure based 
pharmacophore model. 
 
Hydrogen bond features are described by direction 
and distance constraints in contrary to hydrophobic 
and ionizable areas, which have a distance constraint 
only. 
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4.2 Evaluation of the Model 
 
To evaluate the best performing pharmacophore model, our in-house database was 
screened. This so called MDR-database includes 374 propafenone derivatives containing ac-
tivity data from P-gp efflux assays and therefore provides a quantitative measure for the pre-
dictive quality of the models. All compounds with an activity < 100 nm were defined as inhibi-
tors and all others as non-inhibitors. For the screening process a multi-conformational database 
was generated containing up to 500 conformations per ligand by applying the omega-best 
protocol within LigandScout. Furthermore, all features of the pharmacophore were defined as 
obligatory, although one feature was allowed to be omitted by each compound. To ensure 
that the best conformational fit of each molecule was found, the first-match mode option of 
LigandScout was disabled.  
 
As the MDR database consists mainly of propafenone type P-gp inhibitors, an additional eval-
uation of the pharmacophore model’s predictive quality was performed. Therefore a data-
base with different compound classes was created by combining two P-gp inhibitor sets, pub-
lished by Brocatelli et al.54 and Chen et al.55. These databases hereafter referred to as Broca-
telli dataset and Chen dataset, contain 1.275 respectively 1.273 compounds. For elimination of 
duplicated structures 2D SMILES representations of each compound were used. Consequently 
53 duplicate compounds from the Brocatelli dataset have been removed, whereas no dupli-
cates for the Chen database have been found. Subsequently, 433 compounds were deleted 
as they were found to be present in both of the two datasets. Finally, 108 permanently 
charged molecules have been removed leading to a dataset of 1.954 compounds, compris-
ing 1.208 inhibitors and 532 non-inhibitors, indicated with 1 or 0, respectively (Figure 14). 
 
 
Figure 14: Pie chart of the two initial databases and the fused dataset,  
showing the inhibitor, non-inhibitor relation. 
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As stated above, a multi-conformational database of these inhibitors containing up to 500 
conformations per compound was created, which was screened against the pharmacophore 
model (again one feature was allowed to be omitted) and also here the disable-first-match 
mode was used.  
 
For further evaluation a spiked DUD set was screened. Therefore, the 40 compounds of the 
MDR-database showing activities < 100 nm and the 1.208 P-gp inhibitors of the merged Broca-
telli_Chen dataset were included to a “Directory of Useful Decoys” containing 93.567 struc-
tures.  
 
 
Figure 15: Pie chart of the spiked DUD database, showing the DUD Inhibitors relation 
 
The predictive ability of inhibitor and non-inhibitor classification of the pharmacophore model 
was evaluated in terms of standard parameters derived from confusion matrix based on the 
true positives (TP), false positives (FP), true negatives (TN) and false negatives (FN). Thus, at the 
end of each screening sensitivity, specificity, accuracy, precision and the enrichment factor 
(EF) were calculated.  
 
Sensitivity measures the proportion of all true actives, which are correctly identified as such: 
 !"#$%!"#"!$ =    !"!" + !" 
 
Specificity shows the proportion total number of correctly predicted inactives to the total 
number of inactives: !"#$%&%$%'(   =    !"!" + !" 
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The accuracy is defined as the proportion of true results in the population and thus giving the 
fraction of correctly predicted molecules: !""#$%"&   =    !" + !"!" + !" + !" + !" 
 
On the other hand, precision is the ratio of the true positives against all the positives: 
 !"#$%&%'(   =    !"!" + !" 
 
The enrichment factor measures how known active ligands are enriched in the hit list com-
pared to a random selection: 
 !"#$%&'(")  !"#$%&   =    !"#$%&'(  !"#$%&  !"  !"#!$%!"#$%&'(  !"#$%&  !"  !"#"$"%&  
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4.3 Screening a Commercial Database 
 
In order to test the predictive quality of the final pharmacophore model, the commercial 
LifeChemicals database56, comprising 306.705 compounds has been screened. Due to the 
fact that generation of a multi-conformational database of this huge dataset using the ome-
ga-best option would be a very time-consuming process, the multi-conformational database 
was generated containing up to 25 conformations per ligand by applying the omega-fast pro-
tocol within LigandScout. Here again the first-match mode option of LigandScout was inacti-
vated and all compounds that at least fulfilled all but one pharmacophoric features of the 
model were considered as hits. 
 
Additionally a similarity screen by calculating SHannon Entropy Descriptors (SHED)43 was per-
formed. Thus, similarity matrices of GPV062 against the compounds from the screening library 
were calculated using the command 
 
ph4_SimilarityMatrix[’LifeChem.mdb’, ‘GPV062.mdb’,’FP:SHED’,’IED’,’LifeChem_SHED.txt’] 
 
in the command line of MOE57. Consequently LifeChem.mdb and GPV062 represent the input 
databases, FP:SHED specifies to use SHannon Entropy Descriptors and IED characterizes the 
similarity metric. LifeChem_SHED.txt defines the new output file. Christoph Waglechner modi-
fied the file ph4addfp.svl58 in order to produce a human readable output of this command. 
The resulting matrices were subsequently imported into the LifeChemicals database, showing 
now an additionally column containing the similarity value compared to GPV062 for each 
compound. The 400 compounds, which are most similar to GPV062, were again screened with 
the structure based pharmacophore model. The required multi-conformational database was 
generated with the omega-best mode and this time two features of the pharmacophore 
could be omitted. 
 
Subsequently, selected hits should be tested experimentally for their P-gp inhibiting and for 
their pharmacological chaperone activity. In order to test the P-gp inhibiting activity 
HEK293/EBNA cells were incubated in the presence of different inhibitor concentrations. After-
wards transport of the known P-gp substrate Rhodamine123 was detected by fluorescent 
emission at 534 nm wavelengths. This biological assay is described more detailed by Parveen 
et al.53.  
 
To monitor cell surface expression of the transporter and as a consequence pharmacological 
activity a P-gp specific antibody and flow cytometry as described by Pferschy59 was used. The 
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expression of P-gp mutants in HEK 293 and NIH 3T3 cells in presence of the supposedly phar-
macological chaperones was analyzed using the selective monoclonal antibody MRK16 and 
a FITC-labeled second antibody used in flow cytometry analysis. 
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4.4 Docking 
 
As the next step, all the experimentally tested compounds were docked into the binding site of 
GPV062 in the homology of human P-glycoprotein51. The docking procedure was performed 
with the genetic-algorithm based program GOLD34, which stands for Genetic Optimization for 
Ligand Docking and is provided as a part of the GOLD Suite. However, in order to dock the 
experimentally tested compounds 10 Å around the docking pose of GPV062 were defined as 
binding region, which was kept rigid. The uncharged ligands were treated full flexible. Exact 
adjustments according ligand flexibility are shown in Figure 16.  
 
 
Figure 16: GOLD Setup window, showing the adjustments for ligand flexibility. 
 
GOLD offers four different scoring functions, including GoldScore, ChemScore, Astex Statistical 
Potential (ASP)60 and Piecewise Linear Potential (ChemPLP)61. To generate a wide variety of 
docking poses for each of these four scoring function 50 poses per compound were deter-
mined. Subsequently the docking outcome was energy minimized using the program MOE 
and rescored with the external scoring function XScore39.  
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A problem according scoring functions is that larger molecules tend to be scored better than 
smaller molecules. For this reason, the scoring functions should be corrected for their size, by 
dividing the scoring value by the heavy atom count (score efficiency, SE). This method arises 
from the size independent affinity measure, called ligand efficiency (LE), proposed by Reyn-
olds et al.31. Especially in fragment design, one has to face the problem that smaller fragments 
appear to be less active than larger ones. Thus, the so-called ligand efficiency, which simply 
divides the activity value by the heavy atom count, should be used.31  
 
Reynolds also pointed out, that a disadvantage of LE is its prioritization for small compounds. 
Thus a new measure, called fit quality (FQ), should correct this bias. Also in this work, the con-
cept of FQ was applied to the docking scores. Therefore, the score efficiency (SE) versus the 
heavy atom count was fitted to a linear equation, resulting in the SE_scale value. Finally, the fit 
quality was simply calculated by dividing SE by SE_scale.31  
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5  RESULTS AND DISCUSSION 
5.1 Pharmacophore Model 
 
The structure based pharmacophore model was based on the previously published docking 
pose of the highly active propafenone derivative GPV062 in a homology model of human P-
gp51. In order to select the best performing pharmacophore model our in-house database 
(MDR Database) comprising mostly propafenone-type P-gp inhibitors was screened. The final 
pharmacophore model was the only model, which was able to predict the 4-hydroxy-4-phenyl 
piperidine GPV062 at top. This model, which is shown in Figure 17, is composed of a total of 8 
features. All of the three phenyl rings of the molecule were considered as hydrophobic fea-
tures and the area around the nitrogen atom was defined as positive ionizable feature. As the 
hydroxy group of the 4-hydroxy-4-piperidyl moiety from GPV062 is capable to capture two di-
rections, a donor and an acceptor feature was placed in each direction. Additionally 19 ex-
clusion volumes were added, in order to define the shape of the binding site. 
 
 
Figure 17: Depiction of GPV062 and the binding pocket of P-gp including the final pharmacophore 
model. Yellow spheres represent hydrophobic features, green respectively red arrows describe hydrogen 
bond donor and acceptor features and the positive ionizable area is marked in blue. The grey spheres 
show the exclusion volumes. The textual description of the pharmacophore model is given in the Ap-
pendix. 
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For further evaluation of the model, the confusion matrix parameters for the results of the 
screening of the MDR dataset have been calculated. Therefore, all compounds with an activi-
ty < 100 nM were defined as inhibitors of P-gp and all others as non-inhibitors. According to this 
threshold, the pharmacophore model was able to find 87 hits including 20 active compounds 
and therefore 20 true positives. Thus, an accuracy of 0,77 was achieved, correctly classifying 
77 % of actives and inactives. Furthermore, a specificity of 80 % shows that the pharmaco-
phore model is capable of identifying inactive compounds correctly, resulting in a low false 
positive rate. The calculated enrichment factor at the top ranked 0,5 % of the database was 
9,35 and thus considered as acceptable. Supplementary details of the confusion matrix pa-
rameters are given in Table 2. The top 10 % of the hit list is shown in Figure 19. 
 
 
Figure 19: The 9 best scored hits of the screening of the MDR database, including their pIC50 values ob-
tained from activity data from P-gp efflux assays. 
 
Additionally, a database of P-gp inhibitors with different compound classes than propafenone 
derivatives was screened to check the reliability of the pharmacophore model. From the 1.945 
compounds obtained from Broccatelli et al.54 and Chen et al.55 the pharmacophore model 
was able to find 62 true positives, which actually was not a satisfactory result considering the 
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1.146 false negatives. This relatively large number of false negatives could be due to the poly-
specific nature of P-gp and the fact that some active compounds might bind to different re-
gions in the large binding pocket. However, the model declared only 14 inactive compounds 
as active, which is on the other hand more than a promising result. This high specificity leads to 
the assumption that the pharmacophore model cannot find many actives, but the hits are 
highly probably active. In order to show the ability of the pharmacophore model to find active 
compounds with different scaffolds some selected hits are depicted in Figure 20. 
 
 
Figure 20: Selected hits of the Inhibitor DB screening, showing the ability of the model to identify active 
compounds with a different scaffold to GPV062. 
 
Finally, a spiked DUD set should be screened for further evaluation of the pharmacophore 
model, comprising 93.567 decoys and 1.248 known actives. The pharmacophore model identi-
fied 393 compounds as hits, including 54 true positives. Because of the resulting accuracy of 
about 98 % and the enrichment factor of 8,65 retrieved after screening 0,5 % of the database 
the model was considered as qualified tool for the prediction of P-gp-inhibitors respectively 
pharmacological chaperones for P-gp. 
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Table 2. Confusion matrix parameters of pharmacophore model evaluation 
 MDR DB Brocatelli_Chen DB spiked DUD DB 
N 374 1945 94815 
Actives 40 1208 1248 
Inactives 334 746 93567 
Hits 87 76 393 
TP 20 62 54 
TN 267 732 93228 
FP 67 14 339 
FN 20 1146 1194 
Sensitivity 0,50 0,05 0,04 
Specificity 0,80 0,98 0,99 
Accuracy 0,77 0,41 0,98 
Precision 0,23 0,82 0,14 
EF 0,5 % 9,35 1,29 8,65 
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5.2 Screening a Commercial Database 
 
The screening of the LifeChemicals dataset56 led to the identification of 364 compounds that 
fulfilled 7 out of 8 pharmacophoric features of the model. By visual inspection of the 50 best 
scored hits 6 compounds have been identified for experimental testing. These 6 compounds 
are shown in Figures 22 to 26. Additionally the compounds are shown together with the depic-
tion of the pharmacophore model. The compounds were named according to their 
LifeChemicals code. 
 
 
 
 
Figure 21: Compound F0743-0024, pharmacophore fit score of 77,58 
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Figure 22: Compound F1863, pharmacophore fit score: 77,47 
 
 
 
Figure 23: Compound F0524-0755, pharmacophore fit score: 77,13 
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Figure 24: Compound F3305-0401, pharmacophore fit score: 77,09 
 
 
 
Figure 25: Compound 2074-0598, pharmacophore fit score: 76,94 
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Figure 26: Compound F3385-1203, pharmacophore fit score 76,89 
 
As a next step SHannon Entropy Descriptors (SHED)43 were calculated and the similarity values 
of the compounds of the LifeChemicals against GPV062 were analyzed. Subsequently, the 
410 compounds with a similarity of more than 82 % were screened with the structure based 
pharmacophore model. The SHED profiles of GPV062 and of the 410 compounds are shown in 
Figure 27. The pharmacophore model discovered 18 compounds that fitted at least 6 out of 
the 8 pharmacophoric features. After visual inspection 5 hits were identified for experimental 
testing. The structures of these compounds are shown in Figures 29 to 33. Furthermore, the SHED 
profiles and a depiction of the pharmacophore fit are shown. 
 
 
Figure 27: SHED profiles of GPV062 and of the compounds of the LifeChemicals database  
showing an 82 % similarity to GPV062. 
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Figure 28: Compound F5622-0095, SHED similarity: 85,6 %, pharmacophore fit score: 77,1 
 
 
 
 
Figure 29: Compound F0410-0005, SHED similarity: 84,7 %, pharmacophore fit score: 73,1 
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Figure 30: Compound F5331-0058, SHED similarity: 82,3 %, pharmacophore fit score: 65,6 
 
 
 
 
Figure 31: Compound F264-0361, SHED similarity: 82,9%, pharmacophore fit score: 64,5 
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Figure 32: Compound F0417-0972, SHED similarity: 88,3 %, pharmacophore fit score: 63,1 
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5.3 Experimental Testing 
 
Finally, the eleven selected compounds have been tested for their P-gp inhibiting potentcy as 
well as for their pharmacological chaperone activity.  
 
The P-gp inhibiting quality of the compounds was tested using the Rhodamine efflux assay. 
Very promising, four of the compounds received from the pharmacophore screening showed 
activities in the double-digit µmolar range and two of them even in the single digit range. The 
exact IC50 values are given in Table 3. 
 
Table 3: Inhibitor Activity Values of the Compounds 
Received from the Pharmacophore Screening 
Compound IC50 (µM) 
F0743-0024 1,38 
F1863-0050 57,43 
F0524-0755 75,34 
F3305-0401 5,99 
F2074-0598 40,33 
F3385-1203 56,86 
 
Among the five compounds identified by SHED similarity search in combination with pharma-
cophore screening, two compounds demonstrated activities in the double and again two in 
the single digit µmolar range. One compound showed an IC50 value of 132,34 µM and was 
therefore considered as inactive. The exact IC50 values of these compounds are given in Ta-
ble 4.  
 
Table 4: Inhibitor Activity Values of the Compounds 
Received from SHED Similarity in Combination with 
Pharmacophore Screening 
Compound IC50 (µM) 
F5622-0095 4,05 
F0410-0005 132,34 
F5331-0058 9,39 
F2649-0361 82,48 
F0417-0972 24,38 
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All in all four of the eleven tested compounds demonstrated activities below 10 µM range, and 
only one showed an IC50 value over 100 µM (Figure 33).  
 
 
Figure 33: Pie chart of the screening results, showing the activity of the 11 tested compounds.  
Hence, 4 showed activity below 10 µM, 6 below 100 µM and only one over 100 µM. 
 
Up until the time of completion of this thesis the biological testing regarding pharmacological 
chaperone activity was still in progress. (Univ.-Prof. Dr. Peter Chiba, personal communication) 
However, due to the fact that inhibitors of P-gp act as pharmacological chaperones as well, it 
is to be assumed that the compounds are also active in this context. Actually, initial results in-
dicate that the tested compounds are also active as pharmacological chaperones, and as 
expected show efficiency values one to two orders of magnitude lower than their efflux inhibi-
tory activity.  
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5.4 Docking 
 
The docking software GOLD of CCDC was used to dock the 11 ordered compounds into the 
homology model of human P-gp published by Klepsch et al.51. Determining the four different 
scoring functions in order to generate a wide variety of docking poses led to 200 docking pos-
es per compound. The total of 2.200 docking poses (Figure 34) was then energy minimized and 
rescored with the external scoring function XScore39.   
 
 
 
Figure 34: Distribution of all 2.200 docking poses in the homology model.  
For the docking process the 10 Å around the docking pose of GPV062 were defined as binding region. 
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In order to avoid larger molecules to be scored better, the scoring functions was corrected by 
dividing the scoring value by the heavy atom count leading to the score efficiency (SE). Sub-
sequently, the fit quality (FQ) of the docking poses was calculated. Therefore the score effi-
ciency (SE) versus the heavy atom count was fitted to a linear equation (Figure 35), resulting in 
the SE_scale value: 
 
SE _ scale = !0,0037*HAC + 0,3325  
 
Finally, the fit quality was calculated by dividing SE by SE_scale. 
 
 
 
Figure 35: Correlation Plot, showing the number of heavy atoms in the X-axis and the score efficiency in 
the Y-axis. The resulting linear equation was used to calculate the FQ. 
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According to the FQ the best 1 % respectively the best 10 % of all 2.200 docking results were 
analyzed. The top 1 % of the database includes 16 poses of compound F0417-0972, 4 poses of 
compound F5622-0095 and 2 poses of compound F0743-0024 (Figure 34). Thus, the top 
22 docking poses contain two of the four high active compounds with activities in the single 
digit and one compound with an activity in the double digit µM range (Figure 36). 
 
 
Figure 36: Bar chart of the docking poses found in the top 1 % of the docking results.  
Also the IC50 values according the inhibitor activity of the individual compounds are shown. 
 
Compound F0417-0972 was also the most numerous in the top 10 % of the docking results, with 
86 poses. Second most common compound was F0743-0024 containing 72 docking poses fol-
lowed by compound F5622-0095 with 40 docking poses. However, compound F0410-005, 
which was declared as inactive according to the biological test, was not present at all in the 
best scored 220 docking poses, while at least one pose of all of the high active compounds 
were represented. Further details are shown in Figure 37.  
 
 
Figure 37: Number of poses of the single compounds in the top 10 % of the docking results.  
Above the bars the IC50 values are stated. 
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As a next step the top twenty ranked docking poses of each compound were visually inspect-
ed regarding similarity between docking pose and the conformation of compound found by 
pharmacophoric search. It shows that unanimous poses were rather found for compounds 
with a high biological activity than compounds with a lower activity. The docking pose of the 
inactive compound F0410-0050 is in fact in 16 of 20 cases completely different to the orienta-
tion of the compound of the pharmacophoric search. Selected docking poses of each of the 
11 tested hits are shown in Figure 38 and Figure 39. The conformations found by the pharma-
cophore search are colored in turquoise and the docking poses are colored in purple. For the 
compounds with conformations dissimilar from the pharmacophoric search, the best ranked 
docking pose is shown. For compound F0410-0050 the most common orientation of the first 
10 % of its docking poses is shown.  
 
 
54 
 
Figure 38: Docking poses of the hits identified by the pharmacophore screening. 
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Figure 39: Selected docking poses of the hits identified by the SHED similarity screen in combination with 
the pharmacophore screening. 
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6  CONCLUSION AND OUTLOOK 
 
The study was based on the membrane protein P-glycoprotein (P-gp), a polyspecific efflux 
pump of the ABC transporter family. As overexpression of P-gp is the main reason for multidrug 
resistance (MDR) on the one hand the understanding of the underlying mechanism of drug 
binding and on the other hand the development of new inhibitors is of great importance. The 
major problem of structure based in silico studies of membrane proteins like P-gp is the lack of 
high-resolution structural information. In this study a homology model of P-gp with the binding 
mode of the inhibitor GPV062, published by Klepsch et al.51, was used to build in silico models 
to identify new inhibitors of P-gp.  
 
First of all, a structure based pharmacophore model was built and validated in order to screen 
a large commercial database. This pharmacophore model was highly specific, excluding most 
of the inhibitors of the databases used for validation. The insufficient sensitivity of the model 
was probably due to the large binding pocket of P-gp. However, for this study it was important 
that the model excludes inactive compounds as far as possible, taking on board to miss some 
of the actives. In order to test the prediction quality of the model a commercial database was 
screened and subsequently 6 selected hits were ordered for biological testing. 
 
Additionally to the previous mentioned structure based method a ligand based approach was 
performed to identify new inhibitors by applying similarity screens using descriptors based on 
Shannon entropy. The 410 most similar hits to GPV062 were additionally screened against the 
pharmacophore model, identifying 18 hit from which 5 more were selected for experimental 
testing. The results of the biological testing according the inhibitory activity of the 11 hits were 
very promising, as 4 compounds were showing IC50 values in the single digit µMolar range and 
only one compound was declared as inactive with a IC50 larger than 100 µM. Besides, the in-
active compound violates Lipinski’s rule of five62 regarding weight and lipophilicity so it’s bioa-
vailability is questionable.  
 
As ten of the eleven compound showed at least modest activity, the results strengthen the 
prospective quality of the binding mode of GPV062 published by Klepsch et al.51. Furthermore, 
it could be shown that it is possible to develop structure based in silico models for the identifi-
cation of new inhibitors by means of a protein-ligand complex generated by docking into a 
homology model. Besides, ligand based in silico methods have been successfully combined 
with structure based in silico models in order to identify new hits. Nevertheless, due to the fact 
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that the binding region of P-gp is quite large, one has to bear in mind that the identified active 
compounds may bind to different binding sites in the binding pocket.  
 
Furthermore, P-gp is a useful model system for studying the mechanism of rescue with phar-
macological chaperones. These estimates are not primarily necessary for P-gp but other ABC 
transporters are linked to human diseases due to protein misfolding. As drug substrates and 
inhibitors may act as pharmacological chaperone, one aim of this study has been to develop 
new pharmacological chaperones on the basis of the binding pose of an inhibitor docked into 
a homology model. Therefore the 11 selected hits were tested also for their pharmacochaper-
one activity. Preliminary results suggest indeed that the high active inhibitors were also active 
as pharmacological chaperones. Discovering this can be interesting for the future develop-
ment of compounds acting as pharmacological chaperones in order to overcome autosomal 
recessive disorders like cystic fibrosis or persistent hyperinsulinemic hypoglycemia of infancy. 
 
As a last step, the 11 tested hits were docked into the binding pocket of GPV062. The outcome 
of this docking experiment was compared with the conformations of the compounds found by 
the pharmacophore model, showing that the more active compounds match the orientation 
more likely than the less active compounds. The orientation of the inactive compound is in 
most cases different to the orientation found by the pharmacophore model. The outcome of 
the docking experiment proves that it is an adequate tool for selection of lead candidates. 
However, hit to lead optimization would be the next step in order to increase the activity of the 
compounds. 
 
In conclusion, the aim of the study, namely identifying new ligands that act as inhibitors and 
pharmacological chaperones for P-gp, has been reached. Furthermore, the combination of 
structure as well as ligand based methods proved to be a useful approach for finding structur-
ally diverse hits. 
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8  APPENDIX 
8.1 List of Abbreviations 
 
ABC ATP-Binding Cassette 
ADP Adenosine Diphosphate 
ATP Adenosine Triphosphate 
CTFR Cystic Fibrosis Transmembrane Conductance Regulator 
DUD Directory of Useful Decoys 
EF Enrichment Factor 
ER Endoplasmic Reticulum 
FN False Negative 
FQ Fit Quality 
FP False Positive 
GPCRs G-Protein Coupled Receptor 
HDL High Density Lipoprotein 
IC50 Half Maximal Inhibitors Concentrate 
LBVS Ligand Based Virtual Screening 
LE Ligand Efficiency 
MD Molecular Dynamics 
MDR Multidrug Resistance 
NB Nucleotide-Binding 
P-gp P-Glycoprotein 
QSAR Quantitative Structure Activity Relationship 
SBVS Structure Based Virtual Screening 
SE Score Efficiency 
SHED Shannon Entropy Descriptors 
SUR1 Sulfonylurea Receptor 1 
TM Transmembrane 
TN True Negatives 
TP True Positives 
VS Virtual Screening 
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8.2 Abstract 
 
P-glycoprotein is an ATP depended drug efflux pump belonging to the MDR/TAP subfamily 
characterized by broad substrate specificity. Overexpression of p-glycoprotein is a major rea-
son for multidrug resistance (MDR) and thus responsible for the failure of antibiotic and cancer 
therapies. Therefore, inhibitors of p-glycoprotein are promising candidates for overcoming the 
problem of MDR. Defective folding in P-gp prevents maturation of the protein. The pharmaco-
logical chaperone GPV062 may repair the folding defects either by promoting dimerization of 
the two nucleotide binding (NB) domains or by promoting correct folding of the transmem-
brane (TM) domains.  
 
The aim of our studies was to develop in silico models, which can be used for the identification 
of new inhibitors as well as pharmacochaperones for P-glycoprotein. Two different computa-
tional approaches were used in order to build up screening models. Pharmacophore screen-
ing as well as similarity screening were performed. The LigandScout program package of 
Inte:Ligand GmbH was used for the construction of a structure-based pharmacophore model, 
taking a complex of GPV062 bound to P-glycoprotein as a starting point, whereas the similarity 
screens were performed according to SHED similarity, using a script embedded in the MOE 
molecular modeling program package.	   In order to validate the method, the pharmacophore 
model was tested against a database consisting of 1.954 compounds classified as active and 
inactive according to the literature. The Precision as well as the Specificity values of 0,82 and 
0,98, respectively, demonstrated the reliability of the model.  
 
Next step was the screening of the LifeChemicals Database containing more than 300.000 
compounds against the pharmacophore model, resulting in the identification of 364 hits. In 
parallel a SHED similarity screen at a threshold of 82% was performed. This led to the acquisition 
of 410 additional hits that were further reduced by comparing their pharmacophoric fits, thus 
identifying 18 compounds matching at least 6 of 8 features of the pharmacophore. Subse-
quently 11 compounds were ordered to test the biological activity according the inhibitor and 
the pharmacological chaperone activity. Among those, four compounds show IC50 values in 
the single digit and six in the double digit µMolar range. Only one compound was declared as 
inactive, showing an IC50 value of more than 100 µMolar.  Finally the 11 experimentally tested 
hits were docked into the binding site of GPV062 in the homology model of P-gp using the ge-
netic-algorithm based program GOLD. The outcome of the docking process was rescored with 
reference to the molecular size of the individual hits and subsequently statistically and visually 
analyzed. The results of the docking experiment are in accordance with the results of the bio-
logical testing. 
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8.3 Zusammenfassung 
 
P-Glykoprotein, eine ATP-abhängige Effluxpumpe aus der MDR/TAP-Unterfamilie, ist durch eine 
breite Substratspezifität charakterisiert. Überexpression von P-Glykoprotein ist ein wesentlicher 
Grund für Resistenzen und damit unter anderem verantwortlich für das Scheitern von Antibioti-
ka und Tumortherapien. Daher sind Inhibitoren dieses Transporters vielversprechende Kandida-
ten zur Überwindung dieser Resistenzentwicklung. Defekte Faltung in P-gp verhindert die Rei-
fung des Proteins. Das pharmakologische Chaperon GPV062 kann durch Dimerisierung der 
zwei Nukleotid-Bindungsdomänen, beziehungsweise durch korrekte Faltung der Transmemb-
randomänen die Reifung des Proteins bewirken.  
 
Das Ziel unserer Studien war es in silico Modelle zu entwickeln, die für die Identifizierung von 
neuen Inhibitoren sowie von Pharmacochaperone für P-Glycoprotein verwendet werden kön-
nen. Sowohl Struktur-basierte als auch Liganden-basierte computergestützte Ansätze wurden 
verwendet um Screening-Modelle zu entwickeln. Mithilfe des Programmpaketes LigandScout 
von Inte:Ligand GmbH wurde ein Struktur-basiertes Pharmakophor-Modell konstruiert, wobei als 
Ausgansstruktur eine validierte Dockingpose von GPV062 in einem Homologiemodell von 
menschlichen P-Glycoprotein diente. Außerdem wurden Ähnlichkeitscreens anhand Shannon-
Entropie durchgeführt, indem ein in MOE eingebettetes Skript angewendet wurde. Um das 
Verfahren zu validieren, wurde das Pharmakophor-Modell anhand einer Datenbank, beste-
hend aus 1954 Verbindungen, die laut Literatur als aktiv und inaktiv deklariert waren, getestet. 
Eine Präzision von 0,82 sowie eine Spezifität von 0,98 demonstrierten die Zuverlässigkeit des 
Modells. 
 
Der nächste Schritt war das Screening der LifeChemicals Datenbank mit mehr als 300.000 Ver-
bindungen gegen das Pharmakophormodell, was zur Identifizierung von 364 Treffern führte. 
Parallel wurden 410 zusätzliche Hits, die eine Ähnlichkeit von mehr als 82 % gegenüber GPV062 
aufweisen, mittels Pharmakophorscreening auf 18 Verbindungen reduziert, wobei mindestens 6 
der 8 Merkmale des Modells gefunden werden mussten. Anschließend wurden 11 Verbindun-
gen auf ihre biologische Aktivität getestet. Es zeigten 4 Verbindungen Aktivitäten im einstelli-
gen und 6 im zweistelligen µM Bereich. Nur eine Verbindung wurde als inaktiv deklariert, da der 
IC50-Wert über 100 µM betrug. Anschließend wurden die 11 experimentell getesteten Verbin-
dungen mit Hilfe des auf genetischen Algorithmus basierten Programms GOLD erneut in das 
Homologiemodell von P-gp gedockt. Das Ergebnis wurde bezugnehmend auf die molekulare 
Größe neu bewertet und anschließend statistisch und visuell analysiert. Die Ergebnisse des Do-
cking-Experiments stimmen mit den Ergebnissen der biologischen Tests überein. 
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8.4 Poster 
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8.5 Textual Description of the Pharmacophore Model  
 
<?xml version="1.0" encoding="UTF-8"?> 
<MolecularEnvironment name="unnamed molecule environment" version="1.4"> 
 <pharmacophore name="*0-1"> 
  <point name="H" featureId="4719875158092691" optional="false" disabled="false" weight="1.0"> 
   <position x3="8.214979" y3="60.74463" z3="-2.853827" tolerance="1.8" /> 
  </point> 
  <point name="H" featureId="471986996515384" optional="false" disabled="false" weight="1.0"> 
   <position x3="17.537054" y3="53.128998" z3="-7.398223" tolerance="1.8" /> 
  </point> 
  <point name="H" featureId="4719873143749448" optional="false" disabled="false" weight="1.0"> 
   <position x3="8.963861" y3="61.639553" z3="4.799777" tolerance="1.8" /> 
  </point> 
  <point name="PI" featureId="48123424544721114" optional="false" disabled="false" weight="1.0"> 
   <position x3="13.552" y3="56.828" z3="-5.023" tolerance="1.8" /> 
  </point> 
  <vector name="HBA" featureId="471986924096081" pointsToLigand="true" hasSyntheticProjectedPoint="false" 
optional="false" disabled="false" weight="1.0"> 
   <origin x3="17.591" y3="59.425" z3="-4.019" tolerance="1.9499999" /> 
   <target x3="16.722" y3="56.794" z3="-6.526" tolerance="1.5" /> 
  </vector> 
  <vector name="HBA" featureId="471986918590479" pointsToLigand="true" hasSyntheticProjectedPoint="false" 
optional="false" disabled="false" weight="1.0"> 
   <origin x3="16.506" y3="58.066" z3="-8.721" tolerance="1.9499999" /> 
   <target x3="16.722" y3="56.794" z3="-6.526" tolerance="1.5" /> 
  </vector> 
  <vector name="HBD" featureId="471986407920626" pointsToLigand="false" hasSyntheticProjectedPoint="false" 
optional="false" disabled="false" weight="1.0"> 
   <origin x3="16.722" y3="56.794" z3="-6.526" tolerance="1.5" /> 
   <target x3="16.506" y3="58.066" z3="-8.721" tolerance="1.9499999" /> 
  </vector> 
  <vector name="HBD" featureId="471986446767528" pointsToLigand="false" hasSyntheticProjectedPoint="false" 
optional="false" disabled="false" weight="1.0"> 
   <origin x3="16.722" y3="56.794" z3="-6.526" tolerance="1.5" /> 
   <target x3="17.591" y3="59.425" z3="-4.019" tolerance="1.9499999" /> 
  </vector> 
  <volume type="exclusion" featureId="4719875476491737" optional="false" disabled="false" weight="1.0"> 
   <position x3="8.512799" y3="56.935596" z3="-5.807801" tolerance="1.5" /> 
  </volume> 
  <volume type="exclusion" featureId="4719875366379721" optional="false" disabled="false" weight="1.0"> 
   <position x3="8.629666" y3="57.228333" z3="0.083666" tolerance="1.5" /> 
  </volume> 
  <volume type="exclusion" featureId="471986448153529" optional="false" disabled="false" weight="1.0"> 
   <position x3="17.591" y3="59.425" z3="-4.019" tolerance="1.0" /> 
  </volume> 
  <volume type="exclusion" featureId="47198783470831090" optional="false" disabled="false" weight="1.0"> 
   <position x3="6.435" y3="57.627" z3="-2.11" tolerance="1.0" /> 
  </volume> 
  <volume type="exclusion" featureId="4719875286683709" optional="false" disabled="false" weight="1.0"> 
   <position x3="8.453" y3="61.175198" z3="-7.429401" tolerance="1.5" /> 
  </volume> 
  <volume type="exclusion" featureId="471986920438480" optional="false" disabled="false" weight="1.0"> 
   <position x3="16.506" y3="58.066" z3="-8.721" tolerance="1.0" /> 
  </volume> 
  <volume type="exclusion" featureId="47198790897571091" optional="false" disabled="false" weight="1.0"> 
   <position x3="12.672" y3="56.678" z3="3.975" tolerance="1.0" /> 
  </volume> 
  <volume type="exclusion" featureId="471987001558888" optional="false" disabled="false" weight="1.0"> 
   <position x3="12.5556" y3="52.772797" z3="-8.552801" tolerance="1.5" /> 
  </volume> 
  <volume type="exclusion" featureId="4719874708407690" optional="false" disabled="false" weight="1.0"> 
   <position x3="8.2516" y3="65.4742" z3="-3.791" tolerance="1.5" /> 
  </volume> 
  <volume type="exclusion" featureId="4719875181962693" optional="false" disabled="false" weight="1.0"> 
   <position x3="8.239" y3="65.303" z3="-0.94" tolerance="1.5" /> 
  </volume> 
  <volume type="exclusion" featureId="4719870227726116" optional="false" disabled="false" weight="1.0"> 
   <position x3="14.911" y3="52.033" z3="-9.626001" tolerance="1.5" /> 
  </volume> 
  <volume type="exclusion" featureId="4719873215745457" optional="false" disabled="false" weight="1.0"> 
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   <position x3="6.198999" y3="63.323" z3="1.588" tolerance="1.5" /> 
  </volume> 
  <volume type="exclusion" featureId="471986999556886" optional="false" disabled="false" weight="1.0"> 
   <position x3="20.829918" y3="54.690346" z3="-6.0043197" tolerance="1.5" /> 
  </volume> 
  <volume type="exclusion" featureId="4719873237690459" optional="false" disabled="false" weight="1.0"> 
   <position x3="6.594999" y3="57.477" z3="4.815999" tolerance="1.5" /> 
  </volume> 
  <volume type="exclusion" featureId="47198791759981092" optional="false" disabled="false" weight="1.0"> 
   <position x3="11.558" y3="61.013" z3="8.052" tolerance="1.0" /> 
  </volume> 
  <volume type="exclusion" featureId="4719873161459449" optional="false" disabled="false" weight="1.0"> 
   <position x3="4.822" y3="60.707" z3="5.711999" tolerance="1.5" /> 
  </volume> 
  <volume type="exclusion" featureId="4719870209246114" optional="false" disabled="false" weight="1.0"> 
   <position x3="16.551" y3="49.45" z3="-11.447" tolerance="1.5" /> 
  </volume> 
  <volume type="exclusion" featureId="471986941536683" optional="false" disabled="false" weight="1.0"> 
   <position x3="20.363667" y3="51.01267" z3="-10.998334" tolerance="1.5" /> 
  </volume> 
  <volume type="exclusion" featureId="4719872617448447" optional="false" disabled="false" weight="1.0"> 
   <position x3="7.318999" y3="58.671" z3="9.081999" tolerance="1.5" /> 
  </volume> 
 </pharmacophore> 
 <properties /> 
 <viewerProperties> 
  <viewerProperty name="showpharmacophore" value="true" /> 
  <viewerProperty name="proteinbackbonemode" value="DONT" /> 
  <viewerProperty name="envrenderstyle" value="Line" /> 
  <viewerProperty name="nonstdrenderstyle" value="Don't Show" /> 
  <viewerProperty name="corerenderstyle" value="Stick" /> 
  <viewerProperty name="corehydrogenmode" value="SHOW" /> 
  <viewerProperty name="envhydrogenmode" value="false" /> 
  <viewerProperty name="depthOffset" value="-0.05979824" /> 
  <viewerProperty name="cameradistance" value="68.9806" /> 
  <viewerProperty name="transform" value="0.2531001, -0.7782681, -0.5746665, 0.0, 0.5153797, -0.39423072, 
0.7608975, 0.0, -0.81873435, -0.4887543, 0.3013238, 0.0, 0.0, 0.0, 0.0, 1.0" /> 
  <viewerProperty name="rendercenterz" value="-1.1825004" /> 
  <viewerProperty name="pany" value="0.7969208" /> 
  <viewerProperty name="rendercentery" value="57.462097" /> 
  <viewerProperty name="panx" value="-0.43128014" /> 
  <viewerProperty name="rendercenterx" value="12.825959" /> 
  <viewerProperty name="rotationcenterz" value="-1.1825004" /> 
  <viewerProperty name="rotationcentery" value="57.462097" /> 
  <viewerProperty name="rotationcenterx" value="12.825959" /> 
 </viewerProperties> 
</MolecularEnvironment> 
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